Literature DB >> 26222761

Glycoprofiling effects of media additives on IgG produced by CHO cells in fed-batch bioreactors.

Helene Faustrup Kildegaard1,2, Yuzhou Fan1,3, Jette W Sen3, Bo Larsen1, Mikael R Andersen4.   

Abstract

Therapeutic monoclonal antibodies (mAbs) are mainly produced by heterologous expression in Chinese hamster ovary (CHO) cells. The glycosylation profile of the mAbs has major impact on the efficacy and safety of the drug and is therefore an important parameter to control during production. In this study, the effect on IgG N-glycosylation from feeding CHO cells with eight glycosylation precursors during cultivation was investigated. The study was conducted in fed-batch mode in bioreactors with biological replicates to obtain highly controlled and comparable conditions. We assessed charge heterogeneity and glycosylation patterns of IgG. None of the eight feed additives caused statistically significant changes to cell growth or IgG productivity, compared to controls. However, the addition of 20 mM galactose did result in a reproducible increase of galactosylated IgG from 14% to 25%. On the other hand, addition of 20 mM N-acetyl-D-glucosamine (GlcNAc) reduced relative abundance of galactosylated IgG by 4%. Additionally, supplementation with 10 mM mannose slightly reduced GlcNAc occupancy of IgG. Overall, comparing the effects of IgG glycosylation, by supplementing the cell culture medium with glycosylation precursors during cultivation, revealed an application of these glycosylation precursors for modulating N-glycosylation of IgG.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Chinese hamster ovary cells; IgG; fed-batch; glycosylation; medium additives

Mesh:

Substances:

Year:  2015        PMID: 26222761     DOI: 10.1002/bit.25715

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

2.  Comprehensive manipulation of glycosylation profiles across development scales.

Authors:  Sven Loebrich; Elisa Clark; Kristina Ladd; Stefani Takahashi; Anna Brousseau; Seth Kitchener; Robert Herbst; Thomas Ryll
Journal:  MAbs       Date:  2018-10-22       Impact factor: 5.857

3.  Real-time quantification and supplementation of bioreactor amino acids to prolong culture time and maintain antibody product quality.

Authors:  David N Powers; Yifan Wang; Erica J Fratz-Berilla; Sai Rashmika Velugula-Yellela; Brittany Chavez; Phillip Angart; Nicholas Trunfio; Seongkyu Yoon; Cyrus Agarabi
Journal:  Biotechnol Prog       Date:  2019-08-28

4.  Multivariate data analysis of growth medium trends affecting antibody glycosylation.

Authors:  David N Powers; Nicholas Trunfio; Sai R Velugula-Yellela; Phillip Angart; Anneliese Faustino; Cyrus Agarabi
Journal:  Biotechnol Prog       Date:  2019-10-18

Review 5.  Developments and opportunities in continuous biopharmaceutical manufacturing.

Authors:  Ohnmar Khanal; Abraham M Lenhoff
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

6.  Semi-Automated Glycoproteomic Data Analysis of LC-MS Data Using GlycopeptideGraphMS in Process Development of Monoclonal Antibody Biologics.

Authors:  Kuin Tian Pang; Shi Jie Tay; Corrine Wan; Ian Walsh; Matthew S F Choo; Yuan Sheng Yang; Andre Choo; Ying Swan Ho; Terry Nguyen-Khuong
Journal:  Front Chem       Date:  2021-05-18       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.